7th Eurasian Hematology Oncology Summit
2020 Update on MPNs: What Is the Risk Adapted Management in PV? Is Ropeginterferon Alfa-2b Effective in Inducing CHR? Can We Achieve Both HCT Control and Spleen Response With Ruxolitinib?
By
7th Eurasian Hematology Oncology Summit
FEATURING
Tariq Mughal
By
7th Eurasian Hematology Oncology Summit
FEATURING
Tariq Mughal
Comments 0
Login to view comments.
Click here to Login
